Medical Digest & Congress Report

Professor Silke Gillessen discussing results from STAMPEDE trial assessing the addition of metformin to ADT for patients with mHSPC.

Video: https://medicaldigest.org/scientific-contents/interview:adding-metformin-adt-patients-mhspc-overall-survival-results-multi-arm-multi-stage-randomized-platform-trial-stampede

Professor Silke Gillessen presented new results from the PEACE-3 trial at the 2024 ESMO conference. This study indicates that combining Enzalutamide with Radium223 significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases over Enzalutamide alone.

Video: https://medicaldigest.org/scientific-contents/interview:peace-3-trial-shows-combination-therapy-improves-survival-prostate-cancer-report-esmo2024

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC.

Video: https://medicaldigest.org/scientific-contents/interview:neoadjuvant-pembrolizumab-or-placebo-plus-chemotherapy-followed-adjuvant-pembrolizumab-or-placebo-high-risk-early-stage-tnbc-overall-survival-results-phase-3-keynote-522-study

Professor Dominik P. Modest shares his thoughts on POD1UM-303/InterAACT 2 study, which are potentially practice-changing findings in squamous cell carcinoma of the anal canal.

Video: https://medicaldigest.org/scientific-contents/interview:pod1um-303interaact-2-potentially-practice-changing-findings-scac-report-esmo2024

Professor Tony S.K. Mok shares his thoughts on setting a new benchmark for ALK+ aNSCLC targeted therapy.

Video: https://medicaldigest.org/scientific-contents/interview:setting-new-benchmark-alk-ansclc-targeted-therapy-report-esmo2024

Professor Ann Partridge shares his thoughts on breast cancer, early stage highlights of the ESMO 2024 Congress.

Video: https://medicaldigest.org/scientific-contents/interview:breast-cancer-early-stage-highlights-esmo-2024-congress

Professor Remi Nout shares his thoughts on the interim results of the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial that were presented during the ESMO Congress 2024.

Video: https://medicaldigest.org/scientific-contents/interview:adjuvant-pembrolizumabchemotherapy-misses-dfs-end-point-high-risk-endometrial-cancer-benefits-dmmr-subgroup

Professor Remi Nout shares his thoughts on the treatment of cervical cancer in 2024 in the light of KEYNOTE-A18 study.

Video: https://medicaldigest.org/scientific-contents/interview:treatment-cervical-cancer-2024-highlight-keynote-a18-study

Prof. Michael Böhm explains how SGLT-2 inhibitors became a strong pillar of treatment in HFrEF and HFpEF patients. Their antidiabetic effect and kidney protection make them a widely used tool in cardiovascular diseases. We learn where GLP-1 agonists stand in cardiovascular risk protection and how beneficial they are in overweight HFpEF patients. The new mineralocorticoid receptor antagonists (MRAs) also proved their role in HF treatment. The new, non-steroid MRA, finerenone improved CV outcomes in the FINEARTS-HF trial in HFpEF patients, presented at ESC2024. The MOONRAKER program will further investigate finerenone’s place in HF therapy. He stresses that we must use all 4 pillars of HF treatment.

Video: https://medicaldigest.org/scientific-contents/interview:new-pillars-optimal-medical-treatment-heart-failure

Prof. Carlos Robalo Cordeiro, immediate Past-President of the ERS shares his thoughts on the highlights of ERS 2024.

Video: https://medicaldigest.org/scientific-contents/interview:highlihts-ers-2024-presidents-perspective